US Patent Application 20090010962 - Genetically Engineered Swine Influenza Virus and Uses Thereof
Inventors
Assignees
US Classes424/199.1, Recombinant virus encoding one or more heterologous proteins or fragments thereof435/236, Inactivation or attenuation; producing viral subunits424/209.1, Orthomyxoviridae (e.g., influenza virus, fowl plague virus, etc.)435/325ANIMAL CELL, PER SE (E.G., CELL LINES, ETC.); COMPOSITION THEREOF; PROCESS OF PROPAGATING, MAINTAINING OR PRESERVING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF ISOLATING OR SEPARATING AN ANIMAL CELL OR COMPOSITION THEREOF; PROCESS OF PREPARING A COMPOSITION CONTAINING AN ANIMAL CELL; CULTURE MEDIA THEREFOREAttorney, Agent or FirmInternational ClassesC12N 7/00C12N 5/10 A61K 39/145 A61P 31/12 C12N 7/04 Abstract textThe present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations. |
| ||||||||||||||
